|Conditional recommendation based on low-quality evidence; may consider tofacitinib if the patient prefers an oral therapy or had a primary TNFi biologic efficacy failure or a TNFi biologicâ€“associated serious adverse effect.| |
|5. Switch to a different TNFi biologic (with or without MTX) over adding MTX to the same TNFi biologic monotherapy (PICO 26 and 26A)|Very low|